BEFORE AND AFTER

Before and After Photos See More Before and After Photos

EFFICACY

Prescription strength TAZORAC® (tazarotene) Cream and Gel 0.1% are clinically shown to have effective acne fighting power for patients 12 years and older.

FOR YOUR PATIENT

Download the Patient Handbook

FULL PRESCRIBING INFORMATION

TAZORAC® (TAZAROTENE) CREAM & GEL 0.1% IMPORTANT INFORMATION

INDICATIONS

TAZORAC® (tazarotene) Cream 0.1% is indicated for acne vulgaris.
TAZORAC® (tazarotene) Gel 0.1% is indicated for mild to moderate facial acne vulgaris

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Retinoids may cause fetal harm when administered to a pregnant woman. TAZORAC® Cream and Gel 0.1% are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus.

TAZORAC® Cream and Gel 0.1% are contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS

Pregnancy Category X. Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC® Cream or Gel 0.1% is used. The possibility that a woman of childbearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mlU/mL for hCG should be obtained within 2 weeks prior to TAZORAC® Cream or Gel 0.1% therapy, which should begin during a normal menstrual period.

PRECAUTIONS

Retinoids should not be used on eczematous skin, as they may cause severe irritation.

TAZORAC® Cream or Gel 0.1% should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity. Patients must be warned to use sunscreens (minimum SPF 15) and protective clothing when using TAZORAC® Cream and Gel 0.1%. Concomitant dermatologic agents that have a strong drying effect should be avoided.

ADVERSE REACTIONS

The most frequent adverse reactions reported during clinical trials with TAZORAC® Cream 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation. The most frequent adverse events reported with TAZORAC® Gel 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.